Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

Genentech submits sBLA for diabetic retinopathy drug to FDA

Genentech, Inc., a biotechnology company, has submitted a supplemental biologics license application, or sBLA, for Lucentis to the FDA for the treatment of diabetic retinopathy.

Published By MarketLine
25 Aug 2014
NewsWire
NewsWire

Aetna announces collaboration with Alegent Creighton Health and UniNet

Aetna Inc., a managed health care company, Alegent Creighton Health and its provider-led clinically integrated network, UniNet, have announced a new collaboration that will offer self-insured employers low-priced and quality health care for their employees and their families.

Published By MarketLine
25 Aug 2014
NewsWire
NewsWire

OPKO's Phase III secondary hyperparathyroidism trial meets primary endpoints

OPKO Health, Inc., a biopharmaceutical and diagnostics company, has announced positive results from the first pivotal Phase III trial of Rayaldee, which is one of two identical randomized, double-blind, placebo-controlled, multi-site study intended as a new treatment for secondary hyperparathyroidism, or SHPT, in patients with stage 3 or 4 chronic kidney disease, or CKD, and vitamin D insufficiency.

Published By MarketLine
25 Aug 2014
NewsWire
NewsWire

Apricus Biosciences partners with SRF for scleroderma research

Apricus Biosciences, Inc., a pharmaceutical company developing therapeutics for men's and women's health, has announced a multi-year partnership agreement with the Scleroderma Research Foundation, or SRF.

Published By MarketLine
25 Aug 2014
NewsWire
NewsWire

Oncothyreon Q2 net loss decreases

Oncothyreon Inc., a biopharmaceutical company, has reported that net loss for the second quarter ended June 30, 2014 was $6.03 million, or $0.09 loss per share, compared to a net loss of $16.40 million, or $0.28 loss per share, for the same quarter ended June 30, 2013.

Published By MarketLine
25 Aug 2014
NewsWire
NewsWire

NORGINE in-licenses muco-adhesive oral wound rinse from Access in Europe

Norgine B.V., a specialty pharmaceutical company, has entered into a license agreement with Access Pharmaceuticals Inc., a biopharmaceutical company, to develop and commercialize MUGARD, a muco-adhesive oral rinse for the prevention and management of the lesions and symptoms of oral mucositis, in Europe.

Published By MarketLine
25 Aug 2014
NewsWire
NewsWire

CEL-SCI Q2 net loss decreases

CEL-SCI Corporation, a developer of new cancer therapies, has reported that net loss available to the common shareholders for the third quarter ended June 30, 2014 was $2.44 million, or $0.11 loss per diluted share, compared to a net loss available to the common shareholders of $4.51 million, or $0.18 loss per diluted share, for the same quarter ended June 30, 2013.

Published By MarketLine
25 Aug 2014
NewsWire
NewsWire

Genmab's partner Janssen to initiate Phase III multiple myeloma study

Genmab A/S, a biotechnology company, has announced that its collaboration partner, Janssen Biotech, Inc. plans to initiate a new Phase III study of daratumumab in multiple myeloma.

Published By MarketLine
25 Aug 2014
NewsWire
NewsWire

PhotoMedex announces encouraging results from hair regrowth study

PhotoMedex, Inc., a skin health company, has announced that a new independent clinical study demonstrated reduction in hair regrowth following use of no!no! Hair using proprietary Thermicon technology.

Published By MarketLine
25 Aug 2014
NewsWire
NewsWire

Astellas, Cancer Research UK and CRT partner for pancreatic cancer research

Astellas Pharma Inc., a Japanese pharmaceutical company, has announced a new collaboration with Cancer Research UK and its commercial arm, Cancer Research Technology, or CRT, to find new cancer treatment, with an initial focus on pancreatic cancer.

Published By MarketLine
25 Aug 2014

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.